Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16.
Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of the world.
The Consumer Healthcare business reported revenue of 1.2 billion euros in 2Q17, a 42.5% growth at constant exchange rates from 2Q16. Allergy, cough, and cold products reported 42.6% revenue growth to 255 million euros, driven by sales growth of Allegra and Nasacort. Digestive products reported 84.9% revenue growth to 239 million euros, driven by strong digestive product performance.
Revenue from nutritional products rose 54.2% to 170 million euros. Pain products reported 36.4% revenue growth to 297 million euros, driven by strong performance by Doliprane.
To divest company-specific risks, investors could consider the First Trust Value Line Dividend ETF (FVD) which has a 0.5% exposure to Sanofi (SNY). FVD also has a 0.5% exposure to Bristol-Myers Squibb (BMY), a 0.5% exposure to Medtronic (MDT), a 0.5% exposure to Novo Nordisk (NVO), and a 0.5% exposure to Novartis (NVS).